For instance, tumors with signature C1 could benefit of target therapy for tumor suppressors NRSN2 and RBCK1. Classic approaches for targeting of tumor suppressor genes include re-activation, by either re-introducing a functional copy (e.g. gene therapy), or diminishing the repressive action of other players through small molecule inhibition52. The gene discussed is RBCK1; the disease is neoplasm.